351 The Role of Deep Brain Stimulation in Managing Early-Onset Parkinson’s Disease: A Systematic Review and Meta-Analysis of Clinical Outcomes

View at publisher Summarise with VIRAT
Authors: Karlos Acurio, Martin Alonso Hemeryth-Rengifo, Martha Isabel Vilca-Salas, Gustavo A. Quispe-Villegas, Fritz Fidel Váscones-Román, Valeria Abuid Sampelayo, Diana Carolina Salazar Flores, Carlos Quispe-Vicuña, Aldo Flores-Gavino, Brigith Avila, Niels Pacheco-Barrios
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Early-onset Parkinson's Disease (EOPD) is characterized by the onset of core motor symptoms between the ages of 21 and 50. DBS is a widely accepted treatment for Parkinson’s patients whose motor symptoms do not respond adequately to medication. Although recent research advocates for earlier use of DBS, there is limited data specifically addressing its effectiveness in the EOPD population. METHODS: A comprehensive literature search was conducted across PubMed, EMBASE, Web of Science, and Scopus in February 2025, following PRISMA guidelines. Studies reporting DBS outcomes in EOPD patients were included, regardless of the language used or patient age. The main outcomes analyzed were changes in the Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III), Levodopa Equivalent Daily Dose (LEDD), and the Parkinson’s Disease Questionnaire (PDQ-39) scores after surgery. Study quality was assessed using the ROBINS-I tool for non-randomized studies and the JBI checklist for case reports and series. A random-effects meta-analysis was performed to estimate mean differences (MD), with heterogeneity evaluated using the I2 statistic. RESULTS: Out of 3,987 records screened, 68 studies were included (24 cohort studies, 4 case-control studies, and 40 case reports/series), encompassing 2,219 EOPD patients, of whom 805 received DBS. Most patients experienced symptom onset between ages 30–40 and underwent DBS at 50–60 years. The most frequently targeted brain region was the subthalamic nucleus (in 55 of 68 studies). DBS was associated with a mean improvement of -21.03 points in UPDRS-III OFF scores (9 studies; 264 patients; 95% CI: -29.03 to -13.03; I2 = 87%), a mean LEDD reduction of -539.83 mg/day (9 studies; 261 patients; 95% CI: -708.49 to -371.16; I2 = 70%), and a PDQ-39 score improvement of -10.16 points (3 studies; 90 patients; 95% CI: -30.63 to 10.30; I2 = 78%) from baseline to follow-up. Overall, the included studies showed a moderate to high risk of bias. CONCLUSIONS: DBS appears to offer significant benefits in terms of motor function (UPDRS-III) and reduction in medication needs (LEDD) for EOPD patients. However, its impact on quality of life (PDQ-39) remains less clear.

Fields of Study & Subjects

Deep Brain Stimulation and Movement Disorders Obsessive-Compulsive Spectrum Disorders Parkinson's Disease Mechanisms and Treatments

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
93–94
Publication date
26 March 2026
Language
EN